A national register based study examining the prevalence, comorbidities, healthcare resource utilisation and burden of illness of hereditary hypophosphatemia in Demark

Study identification

• EU PAS number:
  EUPAS44133
• Study ID:
  44134
• Official title and acronym:
  A national register based study examining the prevalence, comorbidities, healthcare resource utilisation and burden of illness of hereditary hypophosphatemia in Demark
• DARWIN EU® study:
  No
• Study countries:
  Denmark
• Study description:
  The aims of the current study are twofold 1. first to examine the incidence and prevalence of a confirmed diagnosis of hereditary hypophosphatemia in Denmark across the life span and 2. secondly to understand the life course of the disease and the use of healthcare resources and social benefits compared to a reference population (called the control population). The control population will be used as a baseline and will serve as a comparator to the population with a confirmed diagnosis of hereditary hypophosphatemia (called the case population). We hypothesize that patients with hereditary hypophosphatemia will have progressing and accumulating comorbidities and an increased need for health care services and social benefits compared to the control population, causing a higher level of disease burden.
• Study status:
  Planned

Research institutions and networks

Institutions

Kyowa Kirin

Study timelines

Date when funding contract was signed

Planned:01/06/2021

Actual:01/11/2021

Study start date

Planned:01/12/2021

Date of final study report

Planned:01/11/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Kyowa Kirin

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable